RS61412B1 - Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti - Google Patents

Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti

Info

Publication number: RS61412B1
Authority: RS; Serbia
Prior art keywords: antibodies; functional fragments; tnf alpha; tnf; alpha
Prior art date: 2016-03-17

Application number

RS20210140A

Other languages

English (en)

Inventor

Tea Gunde

Sebastian Meyer

Esther Maria Furrer

Original Assignee

Tillotts Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-03-17

Filing date

2016-03-17

Publication date

2021-03-31

2016-03-17 Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag

2021-03-31 Publication of RS61412B1 publication Critical patent/RS61412B1/sr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

RS20210140A 2016-03-17 2016-03-17 Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti RS61412B1 (sr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP16160918.5A EP3219727B1 (en)	2016-03-17	2016-03-17	Anti-tnf alpha-antibodies and functional fragments thereof

Publications (1)

Publication Number	Publication Date
RS61412B1 true RS61412B1 (sr)	2021-03-31

Family

ID=55542579

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RS20210140A RS61412B1 (sr)	2016-03-17	2016-03-17	Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti

Country Status (27)

Country	Link
US (1)	US10975143B2 (sr)
EP (2)	EP3219727B1 (sr)
JP (1)	JP7126485B2 (sr)
KR (1)	KR102474765B1 (sr)
CN (1)	CN109071651B (sr)
AR (1)	AR107916A1 (sr)
BR (1)	BR112018067713A2 (sr)
CA (1)	CA3011786A1 (sr)
CY (1)	CY1123781T1 (sr)
DK (1)	DK3219727T3 (sr)
EA (1)	EA201892097A1 (sr)
ES (1)	ES2843974T3 (sr)
HR (1)	HRP20210120T1 (sr)
HU (1)	HUE052869T2 (sr)
IL (1)	IL261140B2 (sr)
JO (1)	JOP20170063B1 (sr)
LT (1)	LT3219727T (sr)
MA (1)	MA43738A (sr)
PL (1)	PL3219727T3 (sr)
PT (1)	PT3219727T (sr)
RS (1)	RS61412B1 (sr)
SG (1)	SG11202000029PA (sr)
SI (1)	SI3219727T1 (sr)
SM (1)	SMT202000703T1 (sr)
TW (1)	TWI758280B (sr)
UY (1)	UY37158A (sr)
WO (1)	WO2017158097A1 (sr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA039201B1 (ru)	2016-03-17	2021-12-16	Нумаб Инновейшн Аг	Антитела к фно и их функциональные фрагменты
SI3219726T1 (sl)	2016-03-17	2021-02-26	Tillotts Pharma Ag	Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti
US10787508B2 (en)	2016-03-17	2020-09-29	Numab Innovation Ag	Anti-TNFα-antibodies and functional fragments thereof
CN118873822A (zh)	2016-12-14	2024-11-01	比奥拉治疗股份有限公司	使用tnf抑制剂治疗胃肠道疾病
CA3055256A1 (en) *	2017-03-09	2018-09-13	Mab Discovery Gmbh	Antibodies specifically binding to human il-1r7
EP3810095A1 (en)	2018-06-20	2021-04-28	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
WO2020051275A1 (en) *	2018-09-05	2020-03-12	The Board Of Regents Of The University Of Texas System	Monoclonal antibodies against endotrophin and the use thereof
CA3120619A1 (en)	2018-11-19	2020-05-28	Progenity, Inc.	Methods and devices for treating a disease with biotherapeutics
WO2020114616A1 (en)	2018-12-07	2020-06-11	Tillotts Pharma Ag	Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
WO2021119482A1 (en)	2019-12-13	2021-06-17	Progenity, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
ATE356869T1 (de)	1990-01-12	2007-04-15	Amgen Fremont Inc	Bildung von xenogenen antikörpern
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de)	1990-08-29	1998-02-19	Genpharm Int	Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
GB9109645D0 (en)	1991-05-03	1991-06-26	Celltech Ltd	Recombinant antibodies
US5919452A (en)	1991-03-18	1999-07-06	New York University	Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
MX9204374A (es)	1991-07-25	1993-03-01	Idec Pharma Corp	Anticuerpo recombinante y metodo para su produccion.
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt)	1991-12-02	2008-12-22	Medical Res Council	Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
NO309690B1 (no)	1995-01-23	2001-03-12	Western Atlas Int Inc	Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
EP1978033A3 (en)	1995-04-27	2008-12-24	Amgen Fremont Inc.	Human antibodies derived from immunized xenomice
CA2219486A1 (en)	1995-04-28	1996-10-31	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
JP4215172B2 (ja)	1996-12-03	2009-01-28	アムジェンフレモントインク．	複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
ATE200679T1 (de)	1997-04-14	2001-05-15	Micromet Ag	Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
WO2000029584A1 (en)	1998-11-18	2000-05-25	Genentech, Inc.	Antibody variants with higher binding affinity compared to parent antibodies
GB0412181D0 (en)	2004-06-01	2004-06-30	Celltech R&D Ltd	Biological products
US7431927B2 (en)	2005-03-24	2008-10-07	Epitomics, Inc.	TNFα-neutralizing antibodies
US7592429B2 (en) *	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
DK2390267T3 (da)	2005-06-07	2013-08-26	Esbatech A Novartis Co Llc	Stabile og opløselige antistoffer, der hæmmer TNF(alfa)
KR101834797B1 (ko)	2008-06-25	2018-03-07	에스바테크 - 어 노바티스 컴파니 엘엘씨	보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
WO2009155723A2 (en)	2008-06-25	2009-12-30	Esbatech, An Alcon Biomedical Research Unit Llc	STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
RU2522245C2 (ru)	2008-07-10	2014-07-10	ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи	Способы и композиции для улучшенной доставки макромолекул
BR112012025568A2 (pt) *	2010-04-07	2017-03-28	Abbvie Inc	proteínas de ligação ao tnf-<244>.
EP2593476A2 (en) *	2010-07-16	2013-05-22	Ablynx N.V.	Modified single domain antigen binding molecules and uses thereof
WO2012041018A1 (zh) *	2010-09-30	2012-04-05	成都康弘生物科技有限公司	抗TNFα的人源化抗体及其抗原结合片段Fab和用途
CA2816291C (en) *	2010-10-29	2016-08-23	Daiichi Sankyo Company, Limited	Anti-dr5 antibody
WO2014089111A1 (en) *	2012-12-05	2014-06-12	Novartis Ag	Compositions and methods for antibodies targeting epo
SG11201509899PA (en)	2013-06-26	2016-01-28	Numab Ag	Novel antibody frameworks
US9416197B2 (en) *	2013-11-01	2016-08-16	Ibc Pharmaceuticals, Inc.	Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease
WO2015089283A1 (en) *	2013-12-11	2015-06-18	Cytomx Therapeutics, Inc.	Antibodies that bind activatable antibodies and methods of use thereof
KR20160142849A (ko) *	2014-03-26	2016-12-13	셀 메디카 스위처란트 아게	Tnf 알파에 대한 결합 구성원
SI3219726T1 (sl)	2016-03-17	2021-02-26	Tillotts Pharma Ag	Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti
US10787508B2 (en)	2016-03-17	2020-09-29	Numab Innovation Ag	Anti-TNFα-antibodies and functional fragments thereof
EA039201B1 (ru)	2016-03-17	2021-12-16	Нумаб Инновейшн Аг	Антитела к фно и их функциональные фрагменты

2016
- 2016-03-17 PT PT161609185T patent/PT3219727T/pt unknown
- 2016-03-17 RS RS20210140A patent/RS61412B1/sr unknown
- 2016-03-17 EP EP16160918.5A patent/EP3219727B1/en active Active
- 2016-03-17 PL PL16160918T patent/PL3219727T3/pl unknown
- 2016-03-17 HU HUE16160918A patent/HUE052869T2/hu unknown
- 2016-03-17 SM SM20200703T patent/SMT202000703T1/it unknown
- 2016-03-17 LT LTEP16160918.5T patent/LT3219727T/lt unknown
- 2016-03-17 ES ES16160918T patent/ES2843974T3/es active Active
- 2016-03-17 DK DK16160918.5T patent/DK3219727T3/da active
- 2016-03-17 SI SI201631041T patent/SI3219727T1/sl unknown
2017
- 2017-03-16 BR BR112018067713A patent/BR112018067713A2/pt unknown
- 2017-03-16 EP EP17712725.5A patent/EP3430045B1/en active Active
- 2017-03-16 MA MA043738A patent/MA43738A/fr unknown
- 2017-03-16 EA EA201892097A patent/EA201892097A1/ru unknown
- 2017-03-16 JP JP2019500014A patent/JP7126485B2/ja active Active
- 2017-03-16 WO PCT/EP2017/056246 patent/WO2017158097A1/en active Application Filing
- 2017-03-16 CA CA3011786A patent/CA3011786A1/en active Pending
- 2017-03-16 JO JOP/2017/0063A patent/JOP20170063B1/ar active
- 2017-03-16 CN CN201780015299.XA patent/CN109071651B/zh active Active
- 2017-03-16 US US16/085,543 patent/US10975143B2/en active Active
- 2017-03-16 KR KR1020187026446A patent/KR102474765B1/ko active Active
- 2017-03-16 SG SG11202000029PA patent/SG11202000029PA/en unknown
- 2017-03-17 UY UY0001037158A patent/UY37158A/es not_active Application Discontinuation
- 2017-03-17 AR ARP170100674A patent/AR107916A1/es unknown
- 2017-03-17 TW TW106108829A patent/TWI758280B/zh active
2018
- 2018-08-13 IL IL261140A patent/IL261140B2/en unknown
2021
- 2021-01-22 HR HRP20210120TT patent/HRP20210120T1/hr unknown
- 2021-01-22 CY CY20211100049T patent/CY1123781T1/el unknown

Also Published As

Publication number	Publication date
CY1123781T1 (el)	2022-05-27
TW201739765A (zh)	2017-11-16
BR112018067713A2 (pt)	2019-01-08
WO2017158097A1 (en)	2017-09-21
ES2843974T3 (es)	2021-07-21
IL261140B2 (en)	2023-04-01
MA43738A (fr)	2018-11-28
EP3430045B1 (en)	2023-08-23
CA3011786A1 (en)	2017-09-21
SG11202000029PA (en)	2020-02-27
LT3219727T (lt)	2021-02-10
HRP20210120T1 (hr)	2021-03-05
SI3219727T1 (sl)	2021-04-30
EP3219727B1 (en)	2020-12-16
US20200299375A1 (en)	2020-09-24
US10975143B2 (en)	2021-04-13
CN109071651B (zh)	2022-08-30
PL3219727T3 (pl)	2021-05-17
JOP20170063B1 (ar)	2021-08-17
IL261140A (en)	2018-10-31
JP7126485B2 (ja)	2022-08-26
DK3219727T3 (da)	2021-01-04
EA201892097A1 (ru)	2019-02-28
AR107916A1 (es)	2018-06-28
EP3430045A1 (en)	2019-01-23
HUE052869T2 (hu)	2021-05-28
PT3219727T (pt)	2021-01-21
KR20180118671A (ko)	2018-10-31
KR102474765B1 (ko)	2022-12-06
JP2019512269A (ja)	2019-05-16
TWI758280B (zh)	2022-03-21
EP3219727A1 (en)	2017-09-20
IL261140B (en)	2022-12-01
CN109071651A (zh)	2018-12-21
SMT202000703T1 (it)	2021-01-05
UY37158A (es)	2017-10-31

Publication	Publication Date	Title
IL283321A (en)	2021-07-29	Antibodies against muc16 and their uses
HK1254861A1 (zh)	2019-07-26	抗lag3抗體及其用途
HK1250238A1 (zh)	2018-12-07	抗angptl8抗體及其用途
HK1256381A1 (zh)	2019-09-20	抗pacap抗體及其用途
IL261140B (en)	2022-12-01	Antibodies against tnf-alpha and functional fragments thereof
ZA202108602B (en)	2022-03-30	Anti-tnfalpha-antibodies and functional fragments thereof
GB201503387D0 (en)	2015-04-15	Anti-carbapenem antibodies and uses thereof
PL3292154T3 (pl)	2022-04-19	Przeciwciała przeciwko ludzkiemu HER3 i ich zastosowania
IL261261A (en)	2018-10-31	Antibodies against tnf-alpha and functional fragments thereof
HK1254240A1 (zh)	2019-07-12	抗羥腐胺賴氨酸抗體及其用途
IL261098A (en)	2018-10-31	Antibodies against tnf-alpha and functional fragments thereof
IL261793A (en)	2018-10-31	Anti-tnfalpha antibodies and their functional parts
AU2017235061A1 (en)	2017-09-21	Anti-TNFalpha-antibodies and functional fragments thereof